Complex Civil Litigation Law Firm

If you suffered significant losses in Helen of Troy stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helen of Troy Limited (“Helen of Troy” or the “Company”) (NASDAQ: HELE). STOCK DROP: On October 9, 2025, Helen of Troy reported financial results for the second quarter of fiscal 2026, revealing an approximately 8.9% year-over-year decline in consolidated net sales to roughly $431.8 million. The Company also reported a GAAP diluted loss per share of $13.44, driven in part by significant charges, and adjusted diluted earnings per share of approximately $0.59, down substantially from $1.21 in the prior-year period. Following this news, Helen of Troy’s common stock declined sharply. The Company’s shares fell $6.90 per share, or approximately 25.0%, to close at $20.71 per share on October 9, 2025.

If you purchased or acquired securities in Enphase between April 22, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enphase Energy, Inc. (“Enphase” or the “Company”) (NASDAQ: ENPH) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Enphase overstated its ability to manage its channel inventory; (2) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit; (3) accordingly, Enphase overstated its financial and operational prospects; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. Lead Plaintiff Deadline: April 20, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in PayPal between February 25, 2025 and February 2, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASAQ: PYPL) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of PayPal’s salesforce; notably, that it was not truly equipped to execute on the Company’s perceived growth potential and were “too optimistic” as to how easily and expeditiously its staff could change customer adoption. Such statements absent these material facts caused Plaintiff and other shareholders to purchase PayPal’s securities at artificially inflated prices. Lead Plaintiff Deadline: April 20, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its BLA timeline to perform additional studies to supplement its BLA submission; and (3) as a result, Defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis. Lead Plaintiff Deadline: April 13, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.